Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rebecca Brady

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Vaccine|January 2, 2010
A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjectsThomas R Cate, Yolanda Rayford, Diane Niño, et al.
Sexually Transmitted Diseases|October 27, 2004
Return for results after herpes simplex virus type 2 screeningJ Dennis Fortenberry, Gregory D Zimet, Rebecca Brady, et al.
Sexually Transmitted Diseases|October 27, 2004
Predictors of herpes simplex virus type 2 antibody positivity among persons with no history of genital herpesKenneth H Fife, David I Bernstein, Wanzhu Tu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 26, 2024
Summary: Appropriate Use Criteria for the Use of Nuclear Medicine in Fever of Unknown OriginChristopher J Palestro, Gad Abikhzer, Zvi Bar-Sever, et al.
Vaccine|December 20, 2018
A Phase 1 dose escalating study of double mutant heat-labile toxin LTR192G/L211A (dmLT) from Enterotoxigenic Escherichia coli (ETEC) by sublingual or oral immunizationDavid I Bernstein, Marcela F Pasetti, Rebecca Brady, et al.
Vaccine|January 11, 2025
Safety and immunogenicity of ascending doses of influenza A(H7N9) inactivated vaccine with or without MF59®Sharon E Frey, Rebecca Brady, Lisa Jackson, et al.
The Journal of Infectious Diseases|February 26, 2015
Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) VaccinePatricia L Winokur, Shital M Patel, Rebecca Brady, et al.
Vaccine|October 5, 2007
Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjectsRobert B Couch, Patricia Winokur, Rebecca Brady, et al.
JAMA Pediatrics|March 18, 2024
Basic Environmental Supports for Positive Brain and Cognitive Development in the First Year of LifeJoan L Luby, Max P Herzberg, Caroline Hoyniak, et al.
Virology|January 9, 2015
Acetylation of the c-MYC oncoprotein is required for cooperation with the HTLV-1 p30(II) accessory protein and the induction of oncogenic cellular transformation by p30(II)/c-MYCMegan M Romeo, Bookyung Ko, Janice Kim, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Vaccine|January 2, 2010
A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjectsThomas R Cate, Yolanda Rayford, Diane Niño, et al.
Sexually Transmitted Diseases|October 27, 2004
Return for results after herpes simplex virus type 2 screeningJ Dennis Fortenberry, Gregory D Zimet, Rebecca Brady, et al.
Sexually Transmitted Diseases|October 27, 2004
Predictors of herpes simplex virus type 2 antibody positivity among persons with no history of genital herpesKenneth H Fife, David I Bernstein, Wanzhu Tu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 26, 2024
Summary: Appropriate Use Criteria for the Use of Nuclear Medicine in Fever of Unknown OriginChristopher J Palestro, Gad Abikhzer, Zvi Bar-Sever, et al.
Vaccine|December 20, 2018
A Phase 1 dose escalating study of double mutant heat-labile toxin LTR192G/L211A (dmLT) from Enterotoxigenic Escherichia coli (ETEC) by sublingual or oral immunizationDavid I Bernstein, Marcela F Pasetti, Rebecca Brady, et al.
Vaccine|January 11, 2025
Safety and immunogenicity of ascending doses of influenza A(H7N9) inactivated vaccine with or without MF59®Sharon E Frey, Rebecca Brady, Lisa Jackson, et al.
The Journal of Infectious Diseases|February 26, 2015
Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) VaccinePatricia L Winokur, Shital M Patel, Rebecca Brady, et al.
Vaccine|October 5, 2007
Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjectsRobert B Couch, Patricia Winokur, Rebecca Brady, et al.
JAMA Pediatrics|March 18, 2024
Basic Environmental Supports for Positive Brain and Cognitive Development in the First Year of LifeJoan L Luby, Max P Herzberg, Caroline Hoyniak, et al.
Virology|January 9, 2015
Acetylation of the c-MYC oncoprotein is required for cooperation with the HTLV-1 p30(II) accessory protein and the induction of oncogenic cellular transformation by p30(II)/c-MYCMegan M Romeo, Bookyung Ko, Janice Kim, et al.
Pageof 3